Ecully, October 17 2018
Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), completed all the regulatory steps and can market its Mont-Blanc Evo product line (presented at the Eurospine conference) in the United States.
This development of the flagship Mont-Blanc line that is already distributed on territory provides surgeons with an implant that can be screwed twice as fast, and with more efficient insertion tools. There will be a standard version (non-sterile) and a “ready-to-use” sterile version, a differenciating feature which is to become popular with US surgeons.
Spineway has already begun production of these new implants and instruments, and should be able to record its first US sales during the first quarter of 2019. In addition, the EC label should be granted in 2019 for distribution throughout Europe and the rest of the world.
Spineway has thus taken its first step toward reconquering the US market and will be accelerating the reorganization of its US subsidiary as per its strategic plan.
SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com
Next communication: Half-year results for 2018 – 24 October 2018
This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.
Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation Award (2013) – INPI Talent award (2015). ISIN: FR0011398874 – ALSPW
David Siegrist – CFO
Jérôme Gacoin / Solène Kennis